- Home
- ATOS vs GRX Comparison
ATOS vs GRX Comparison
Compare ATOS & GRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- GRX
- Stock Information
- Founded
- ATOS 2009
- GRX 2007
- Country
- ATOS United States
- GRX United States
- Employees
- ATOS N/A
- GRX N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- GRX Finance/Investors Services
- Sector
- ATOS Health Care
- GRX Finance
- Exchange
- ATOS Nasdaq
- GRX Nasdaq
- Market Cap
- ATOS 140.9M
- GRX 151.1M
- IPO Year
- ATOS 2012
- GRX N/A
- Fundamental
- Price
- ATOS $0.96
- GRX $9.65
- Analyst Decision
- ATOS Strong Buy
- GRX
- Analyst Count
- ATOS 3
- GRX 0
- Target Price
- ATOS $7.00
- GRX N/A
- AVG Volume (30 Days)
- ATOS 952.6K
- GRX 39.7K
- Earning Date
- ATOS 11-12-2024
- GRX 01-01-0001
- Dividend Yield
- ATOS N/A
- GRX 5.98%
- EPS Growth
- ATOS N/A
- GRX N/A
- EPS
- ATOS N/A
- GRX 0.26
- Revenue
- ATOS N/A
- GRX N/A
- Revenue This Year
- ATOS N/A
- GRX N/A
- Revenue Next Year
- ATOS N/A
- GRX N/A
- P/E Ratio
- ATOS N/A
- GRX $38.50
- Revenue Growth
- ATOS N/A
- GRX N/A
- 52 Week Low
- ATOS $0.73
- GRX $7.73
- 52 Week High
- ATOS $2.31
- GRX $10.40
- Technical
- Relative Strength Index (RSI)
- ATOS 24.57
- GRX 20.82
- Support Level
- ATOS $1.17
- GRX $10.06
- Resistance Level
- ATOS $1.30
- GRX $10.11
- Average True Range (ATR)
- ATOS 0.08
- GRX 0.14
- MACD
- ATOS -0.02
- GRX -0.09
- Stochastic Oscillator
- ATOS 1.09
- GRX 6.52
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About GRX The Gabelli Healthcare & Wellness Trust of Beneficial Interest
Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.